EDGEWISE THERAPEUTICS INC (EWTX) — insider trading
Health Care · NASDAQ
EDGEWISE THERAPEUTICS INC (EWTX) has 80 reported SEC Form 4 insider transactions in our data, including 24 open-market sales among the most recent 80 (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Fox Jonathan C | Director | Grant / award / vesting | 308 | — | $0 | Form 4 |
| 2026-08-13 | Donovan Joanne M. | Officer (CMO) | Open-market sale | 2,919 | $43.41 | $126.7K | Form 4 |
| 2026-08-12 | Derakhshan Behrad | Officer (Chief Business Officer) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4/A |
| 2026-08-12 | MOORE JOHN R | Officer (General Counsel) | Grant / award / vesting (derivative) | 65,000 | — | $0 | Form 4/A |
| 2026-08-12 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 65,000 | — | $0 | Form 4/A |
| 2026-08-12 | Donovan Joanne M. | Officer (CMO) | Grant / award / vesting (derivative) | 65,000 | — | $0 | Form 4/A |
| 2026-08-12 | Nofi Michael | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 48,750 | — | $0 | Form 4/A |
| 2026-08-12 | KOCH KEVIN | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 200,000 | — | $0 | Form 4 |
| 2026-08-12 | KOCH KEVIN | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-08-12 | KOCH KEVIN | Director, Officer (President and CEO) | Option exercise / conversion (derivative) | 21,875 | — | $0 | Form 4 |
| 2026-08-12 | KOCH KEVIN | Director, Officer (President and CEO) | Option exercise / conversion (derivative) | 17,969 | — | $0 | Form 4 |
| 2026-08-12 | KOCH KEVIN | Director, Officer (President and CEO) | Open-market sale | 913 | $44.33 | $40.5K | Form 4 |
| 2026-08-12 | KOCH KEVIN | Director, Officer (President and CEO) | Open-market sale | 8,276 | $43.66 | $361.3K | Form 4 |
| 2026-08-12 | KOCH KEVIN | Director, Officer (President and CEO) | Open-market sale | 8,782 | $43.64 | $383.3K | Form 4 |
| 2026-08-12 | KOCH KEVIN | Director, Officer (President and CEO) | Option exercise / conversion | 21,875 | — | $0 | Form 4 |
| 2026-08-12 | KOCH KEVIN | Director, Officer (President and CEO) | Option exercise / conversion | 17,969 | — | $0 | Form 4 |
| 2026-08-12 | Derakhshan Behrad | Officer (Chief Business Officer) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-08-12 | Derakhshan Behrad | Officer (Chief Business Officer) | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-08-12 | Derakhshan Behrad | Officer (Chief Business Officer) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-08-12 | Derakhshan Behrad | Officer (Chief Business Officer) | Option exercise / conversion (derivative) | 5,781 | — | $0 | Form 4 |
| 2026-08-12 | Derakhshan Behrad | Officer (Chief Business Officer) | Open-market sale | 2,475 | $43.70 | $108.2K | Form 4 |
| 2026-08-12 | Derakhshan Behrad | Officer (Chief Business Officer) | Open-market sale | 150 | $44.44 | $6.7K | Form 4 |
| 2026-08-12 | Derakhshan Behrad | Officer (Chief Business Officer) | Open-market sale | 304 | $44.50 | $13.5K | Form 4 |
| 2026-08-12 | Derakhshan Behrad | Officer (Chief Business Officer) | Open-market sale | 2,171 | $43.79 | $95.1K | Form 4 |
| 2026-08-12 | Derakhshan Behrad | Officer (Chief Business Officer) | Option exercise / conversion | 7,500 | — | $0 | Form 4 |
| 2026-08-12 | Derakhshan Behrad | Officer (Chief Business Officer) | Option exercise / conversion | 5,781 | — | $0 | Form 4 |
| 2026-08-12 | MOORE JOHN R | Officer (General Counsel) | Grant / award / vesting (derivative) | 65,000 | — | $0 | Form 4 |
| 2026-08-12 | MOORE JOHN R | Officer (General Counsel) | Grant / award / vesting (derivative) | 32,500 | — | $0 | Form 4 |
| 2026-08-12 | MOORE JOHN R | Officer (General Counsel) | Option exercise / conversion (derivative) | 6,718 | — | $0 | Form 4 |
| 2026-08-12 | MOORE JOHN R | Officer (General Counsel) | Option exercise / conversion (derivative) | 5,781 | — | $0 | Form 4 |
| 2026-08-12 | MOORE JOHN R | Officer (General Counsel) | Open-market sale | 2,419 | $43.80 | $105.9K | Form 4 |
| 2026-08-12 | MOORE JOHN R | Officer (General Counsel) | Open-market sale | 99 | $44.50 | $4.4K | Form 4 |
| 2026-08-12 | MOORE JOHN R | Officer (General Counsel) | Open-market sale | 59 | $44.41 | $2.6K | Form 4 |
| 2026-08-12 | MOORE JOHN R | Officer (General Counsel) | Open-market sale | 2,439 | $43.81 | $106.8K | Form 4 |
| 2026-08-12 | MOORE JOHN R | Officer (General Counsel) | Option exercise / conversion | 6,718 | — | $0 | Form 4 |
| 2026-08-12 | MOORE JOHN R | Officer (General Counsel) | Option exercise / conversion | 5,781 | — | $0 | Form 4 |
| 2026-08-12 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 65,000 | — | $0 | Form 4 |
| 2026-08-12 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 32,500 | — | $0 | Form 4 |
| 2026-08-12 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 7,031 | — | $0 | Form 4 |
| 2026-08-12 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 5,781 | — | $0 | Form 4 |
| 2026-08-12 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Open-market sale | 390 | $44.46 | $17.3K | Form 4 |
| 2026-08-12 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Open-market sale | 2,273 | $43.68 | $99.3K | Form 4 |
| 2026-08-12 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Open-market sale | 3,238 | $43.68 | $141.4K | Form 4 |
| 2026-08-12 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion | 7,031 | — | $0 | Form 4 |
| 2026-08-12 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion | 5,781 | — | $0 | Form 4 |
| 2026-08-12 | Donovan Joanne M. | Officer (CMO) | Grant / award / vesting (derivative) | 65,000 | — | $0 | Form 4 |
| 2026-08-12 | Donovan Joanne M. | Officer (CMO) | Grant / award / vesting (derivative) | 32,500 | — | $0 | Form 4 |
| 2026-08-12 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion (derivative) | 7,031 | — | $0 | Form 4 |
| 2026-08-12 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion (derivative) | 5,781 | — | $0 | Form 4 |
| 2026-08-12 | Donovan Joanne M. | Officer (CMO) | Open-market sale | 800 | $44.52 | $35.6K | Form 4 |
| 2026-08-12 | Donovan Joanne M. | Officer (CMO) | Open-market sale | 104 | $44.43 | $4.6K | Form 4 |
| 2026-08-12 | Donovan Joanne M. | Officer (CMO) | Open-market sale | 2,779 | $43.71 | $121.5K | Form 4 |
| 2026-08-12 | Donovan Joanne M. | Officer (CMO) | Open-market sale | 2,839 | $43.78 | $124.3K | Form 4 |
| 2026-08-12 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion | 7,031 | — | $0 | Form 4 |
| 2026-08-12 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion | 5,781 | — | $0 | Form 4 |
| 2026-08-12 | Nofi Michael | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 48,750 | — | $0 | Form 4 |
| 2026-08-12 | Nofi Michael | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 24,375 | — | $0 | Form 4 |
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 69,648 | — | $0 | Form 4 |
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 130,352 | — | $0 | Form 4 |
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Open-market sale | 69,648 | $39.41 | $2.74M | Form 4 |
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Open-market sale | 130,352 | $39.41 | $5.14M | Form 4 |
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion | 69,648 | $0.18 | $12.5K | Form 4 |
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion | 130,352 | $0.45 | $58.7K | Form 4 |
| 2026-07-01 | Fox Jonathan C | Director | Grant / award / vesting | 319 | — | $0 | Form 4 |
| 2026-06-05 | ROOT JONATHAN D | Director | Grant / award / vesting (derivative) | 16,377 | — | $0 | Form 4 |
| 2026-06-05 | Morris Arlene | Director | Grant / award / vesting (derivative) | 16,377 | — | $0 | Form 4 |
| 2026-06-05 | Thompson Peter A. | Director, 10% owner | Grant / award / vesting (derivative) | 16,377 | — | $0 | Form 4 |
| 2026-06-05 | Brege Laura | Director | Grant / award / vesting (derivative) | 16,377 | — | $0 | Form 4 |
| 2026-06-05 | Fox Jonathan C | Director | Grant / award / vesting (derivative) | 16,377 | — | $0 | Form 4 |
| 2026-06-05 | Martin Christopher Nathan | Director | Grant / award / vesting (derivative) | 16,377 | — | $0 | Form 4 |
| 2026-06-05 | Edris Badreddin | Director | Grant / award / vesting (derivative) | 8,188 | — | $0 | Form 4 |
| 2026-06-05 | Edris Badreddin | Director | Grant / award / vesting (derivative) | 5,619 | — | $0 | Form 4 |
| 2026-05-05 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-05-05 | Donovan Joanne M. | Officer (CMO) | Open-market sale | 50,000 | $38.57 | $1.93M | Form 4 |
| 2026-05-05 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion | 50,000 | $7.08 | $354.0K | Form 4 |
| 2026-05-04 | Donovan Joanne M. | Officer (CMO) | Open-market sale | 5,230 | $31.29 | $163.7K | Form 4 |
| 2026-04-01 | Fox Jonathan C | Director | Grant / award / vesting | 339 | — | $0 | Form 4 |
| 2026-04-01 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion (derivative) | 28,662 | — | $0 | Form 4 |
| 2026-04-01 | Donovan Joanne M. | Officer (CMO) | Open-market sale | 28,662 | $32.31 | $926.1K | Form 4 |
| 2026-04-01 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion | 28,662 | $7.08 | $202.9K | Form 4 |
Ask the chat about EWTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: EDGEWISE THERAPEUTICS INC (EWTX).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.